Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robb Wesselingh

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Epilepsy & Behavior : E&B|May 27, 2022
Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitisRobb Wesselingh, James Broadley, Katherine Buzzard, et al.
The Australian and New Zealand Journal of Psychiatry|October 1, 2020
Neurological, neuropsychiatric and neurodevelopmental complications of COVID-19Christos Pantelis, Mahesh Jayaram, Anthony J Hannan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2011
Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A virusesAlice E Denton, Robb Wesselingh, Stephanie Gras, et al.
Journal of Neurology|June 25, 2024
Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigmsSarah P Griffith, Robb Wesselingh, Nabil Seery, et al.
BMJ Neurology Open|May 13, 2024
Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemicLouise Rath, Wei Zhen Yeh, Angie Roldan, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2024
Language impairments in seropositive and seronegative autoimmune encephalitisSarah P Griffith, Robb Wesselingh, Fiore D'Aprano, et al.
Epilepsia|March 18, 2024
Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE)Daniel J Costello, Elizabeth Matthews, Sidra Aurangzeb, et al.
International Journal of MS Care|June 28, 2021
Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic DisordersLouise Rath, Maria Pia Campagna, Jim Stankovich, et al.
BMJ Neurology Open|February 14, 2025
Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case seriesChristina Kazzi, Ty Simpson, Cassandra Abbott, et al.
Journal of Neuroimmunology|August 14, 2025
Neurotoxicity associated with chimeric antigen receptor T-cell therapyMiriam Wronski, Robb Wesselingh, Christina Kazzi, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Epilepsy & Behavior : E&B|May 27, 2022
Prevalence, risk factors, and prognosis of drug-resistant epilepsy in autoimmune encephalitisRobb Wesselingh, James Broadley, Katherine Buzzard, et al.
The Australian and New Zealand Journal of Psychiatry|October 1, 2020
Neurological, neuropsychiatric and neurodevelopmental complications of COVID-19Christos Pantelis, Mahesh Jayaram, Anthony J Hannan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 1, 2011
Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A virusesAlice E Denton, Robb Wesselingh, Stephanie Gras, et al.
Journal of Neurology|June 25, 2024
Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigmsSarah P Griffith, Robb Wesselingh, Nabil Seery, et al.
BMJ Neurology Open|May 13, 2024
Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemicLouise Rath, Wei Zhen Yeh, Angie Roldan, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2024
Language impairments in seropositive and seronegative autoimmune encephalitisSarah P Griffith, Robb Wesselingh, Fiore D'Aprano, et al.
Epilepsia|March 18, 2024
Clinical outcomes among initial survivors of cryptogenic new-onset refractory status epilepsy (NORSE)Daniel J Costello, Elizabeth Matthews, Sidra Aurangzeb, et al.
International Journal of MS Care|June 28, 2021
Patient Preferences for Time and Location of Infusible Therapies in Multiple Sclerosis and Neuroimmunologic DisordersLouise Rath, Maria Pia Campagna, Jim Stankovich, et al.
BMJ Neurology Open|February 14, 2025
Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case seriesChristina Kazzi, Ty Simpson, Cassandra Abbott, et al.
Journal of Neuroimmunology|August 14, 2025
Neurotoxicity associated with chimeric antigen receptor T-cell therapyMiriam Wronski, Robb Wesselingh, Christina Kazzi, et al.
Pageof 6